TAS-120-301 (2019-004630-42 EudraCT) is a parallel two-arm, randomized study evaluating the efficacy and safety of futibatinib versus gemcitabine–cisplatin as a first-line treatment in patients with advanced, metastatic or recurrent unresectable iCCA harboring FGFR2 gene rearrangements. Here, FGFR2 is linked to infantile convulsions and choreoathetosis.